cyrilzakka/clinical-trials huggingface dataset:
Combined Effects of Barre and Gym Ball Exercises in Primary Dysmenorhoea

Group A will be given Barre and gym ball exercises. Group B will be given Barre exercises. All these sessions will be of 30-minute 3session per week for 12 weeks.

This will be a randomized controlled trial conducted on 42 participants. Data will be collected from USKT (University of Sialkot) and UMT (University of Management and Technology Sialkot by using non-probability convenience sampling technique. WaLLiD score scale is used to determine the severity of dysmenorrhoea. Girls between the age of 17 to 25 with history of dysmenorrhea will be included in this study. Participants who has history of secondary dysmenorrhea, Diagnosed with polycystic ovarian syndrome will be excluded from this study. A sample of 42 will be divided in to two groups with 21 participants in each group. Group A will be given Barre and gym ball exercises. Group B will be given Barre exercises. All these sessions will be of 30 minute 3session per week for 12 weeks. Pre and post assessment of pain, distress , severity of dysmenorrhoea and quality of life will be done by using numeric pain rating scale, menstrual distress questionnaire, WaLLiD scale and Q-LES-Q-SF questionnaire. Data will be analyzed by using SPSS version 26.0.

Eligibility Criteria:
Inclusion Criteria:

* Female suffered from primary dysmenorrhea diagnosed through WaLLiD score range from 5-12
* Female having 5 and above score on Numerical Pain Rating Scale
* Female having regular menstrual period form at least 3 months
* Female having a history of dysmenorrhea occurring at least three times in the past six months

Exclusion Criteria:

* Females using hormonal contraception.
* Females who are married.
* Females with secondary dysmenorrhea
* Females diagnosed with polycystic ovarian syndrome
* Females having menstrual issues
* Females who take analgesic
* Females having BMI \> 25
* Participants who show unwillingness to participate in the study
Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic Data

This study is a prospective, open, not randomized, unilateral multicenter eye study consisting of two study arms to observe the long term satisfaction of patients after an INTRACOR treatment. The satisfaction is determined with the help of the patient perception and the subjective / objective diagnostic data.

The hypothesis of the study is that patients after an INTRACOR treatment are satisfied in the long term.

The study is divided into two study arms. The first study arm includes patients of the preceding study "Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings" and the second study arm includes patients of the previous "Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)".

The hypothesis of the study is that patients after a INTRACOR treatment are satisfied in the long term.

By detailed patient information and a clarification conversation it is guaranteed that every interested and agreeing patient fulfils the inclusion criteria of this study. The quantitative measuring values of the patient perception are assessed by a questionnaire. For measuring the subjective / objective diagnostic data only certificated diagnostic devices are used. No invasive intervention in the eye will be made to change the visual acuity.

Within the scope of the study between 98 and 135 patients should be examined. 49 to 63 patient are intended for the first study arm and 49 to 72 for the second study arm.

The follow-up examinations are carried out at 12 months and/or 24 months as well as for 36 months after the INTRACOR treatment. The study end points are determined for all follow-up examinations. The aim criteria should be reached for the final examination, which is after 36 months, at the latest.

Eligibility Criteria:
Inclusion Criteria:

* Age: at least 18 years old
* Patients must have read, understood and signed the Patient Information
* Patients are willing and able to return for follow-up examinations
* Patient has been already enrolled in the previous study "Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings" or "Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"

Exclusion Criteria:

* Continual wearing of contact lenses before the follow-up examination . Patients must refrain from wearing contact lenses for at least 14 days prior to these dates
* Patients who are pregnant or are lactating
* Patients who are participating in another ophthalmological clinical study except "Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
* severe sick people who cannot give any information on their visual acuity
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.


Eligibility Criteria:
Inclusion Criteria:

* The patient has a diagnosis of Rheumatoid Arthritis based on the American College of Rheumatology (ACR) 1987 Revised Criteria.
* The patient has active disease as defined by both \>=4 tender or painful joints on motion and \>= 4 joints swollen; and either an erythrocyte sedimentation rate (ESR) \> 28 mm or a C-reactive protein (CRP) concentration \> 7 mg/dL.
* Patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity.
* Patient must remain on at least one background traditional disease modifying antirheumatic drug.
* No evidence of inadequately treated latent or active infection with Mycobacterium tuberculosis.

Exclusion Criteria:

* Blood dyscrasias including confirmed: Hemoglobin \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; Absolute neutrophil count \<1.2 x 109/L; Platelet count \<100 x 109/L.
* History of any other rheumatic autoimmune disease other than Sjogren's syndrome.
* No malignancy or history of malignancy.
* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.
Device to Reduce Surgery Site Contamination

The objective of this study is to determine whether the Air Barrier System device reduces airborne particulate and airborne colony forming units present at a surgery site.

The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne contamination. This study examines the hypothesis that the Air Barrier System can reduce the presence of airborne colony-forming units (e.g. bacteria colonies) and particulate at the surgery site.

Eligibility Criteria:
Inclusion Criteria:

* Candidate for primary total hip arthroplasty

Exclusion Criteria:

* Prior history of infection
* Revision arthroplasty
* Screens positive for MRSA
* Undergoing hemiarthroplasty or resurfacing
Silver-Coated vs Standard Catheter for UTI Prevention

Primary Aim: To determine whether silver-coated transurethral catheter decreases the incidence of culture-confirmed urinary tract infection for women with catheter-managed urinary retention after pelvic reconstructive surgery

Secondary Aims:

To assess difference in bacterial uropathogens isolated in urine cultures Adverse symptoms possibly caused by silver-coated catheter


Eligibility Criteria:
Inclusion Criteria:

* Patients who undergo major or minor pelvic organ prolapse surgery of any compartment, or urinary incontinence surgery that are diagnosed with POUR via failed retrograde voiding trial and require an indwelling transurethral catheter upon hospital discharge. Sacral neuromodulation procedures and intradetrusor onabotulinumtoxinA (Botox) injections are excluded.

Exclusion Criteria:

* Unwilling or unable to participate in the study.
* Unwilling or unable to do a catheter self-removal at home.
* Inability to understand English.
* Pregnant women
* Patient personal history of urogenital anomaly, neurogenic bladder, use of chronic self-intermittent catheterization or suprapubic tubes, ureteral stents or other genitourinary indwelling devices, immunosuppressed state or chronic use of steroids.
* Currently (prior 3 months) undergoing medical management for recurrent UTI or interstitial cystitis
* Active urinary tract infection.
* Intraoperative bladder injury or cystotomy
* Physical or mental impairment that would affect the subject's ability to perceive urinary tract infection symptoms
* Reported allergy to silver metal
A Real-time Magnetic Device for Temporary Management of Blepharoptosis

To develop a real-time magnetic device prototype for temporary management of blepharoptosis and evaluate its efficacy and safety, including the gain of palpebral fissure height, visual axis obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid, by performing a human trial on patients with unilateral blepharoptosis.

The magnetic device prototype primarily comprises 2 matched pairs of one near-infrared light-emitting diode and one photodiode sensor, a permanent electromagnetic actuator, an iron sheet (for affixing to the paralytic upper eyelid), and a biosignal acquisition module along with a power supply unit providing a wired connection with optical sensors and a permanent electromagnetic actuator. Before the study, the differences between the affected and unaffected palpebral fissure heights were directly measured using a ruler. During the test after the wearing of the prototype, the distance of the paralytic eyelid lift was documented and the corrected distance (gain) of the paralytic upper eyelid was calculated. The efficacy and safety of the device prototype were assessed. The efficacy was evaluated according to the synchronous blinks and gain of paralytic eyelid lifts. Subjective sensation and complications were assessed by visual axis obstruction, blurred vision, foreign body sensation over the cornea, burning or hot sensation over facial skin, and erythema or pruritus over the eyelid. After the completion of the study procedure, the eyelid skin integrity, subjective sensation and discomfort were examined.

Eligibility Criteria:
Inclusion Criteria:

* Patients with unilateral ptosis; they are capable of understanding and complying with protocol requirements
* Aged 18 years old or older

Exclusion Criteria:

* Upper eyelid scar, contracture, or fibrosis due to previous surgical intervention(s) or traffic accident
* Patients with psychiatric (or mental) disorders; they are unable to cooperate or follow the study procedure
* Children younger than 18 years of age
Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change

The purpose of this study is to investigate the effects of extending the dwell time of peripheral intravenous cannulas on clinical outcomes and cost.

Among hospitalized patients, intravenous therapy is the most common invasive procedure. It is associated with a phlebitis rate of between 1.1% and 63% and a central venous catheter related bacteremia rate of approximately 3.0%. Catheter related blood-stream infections have an attributable mortality rate of 12% to 25%. Factors thought to be associated with these complications include insertion techniques, catheter securement, type of catheter used, type of infusate and additives, post-insertion catheter care and length of time the catheter remains in place.

Current Centers of Disease Control Guidelines provide direction for intravenous therapy management including a recommendation that peripheral intravenous catheters should be re-sited every 72-96 hours. Data underpinning the recommendation was collected in 1992, over a decade ago. Since that time, there have been improvements in catheter design and composition, and prospective surveillance studies have demonstrated the safety of longer dwell times. To date, these observations have not been validated in adults, using randomized controlled trial methodology.

Re-siting intravenous cannulas causes discomfort to patients and has a high recurrent cost. The primary aim of the present study is to compare the rates of peripheral catheter-related blood stream infection, catheter-related local infection, phlebitis and obstruction between two groups of patients - those having routine catheter changes every 72 hours and those having catheter changes only when clinically indicated.

Specific hypotheses:

That changing intravenous peripheral catheters when indicated by clinical signs compared to changing intravenous catheters every 3 days reduces the incidence of intravenous catheter related morbidity.

Eligibility Criteria:
Inclusion Criteria:

Patients are eligible to join the Peripheral Venous Catheter Trial if:

* They are inpatients at the Royal Brisbane and Royal Women's Hospital who are at least 18 years of age

AND

* They are scheduled or expected to have a peripheral venous catheter indwelling for at least 4 days.

AND

* They have had their catheter inserted by a nurse from the IV Therapy Team

Exclusion Criteria:

* Patients with an existing bloodstream infection
* Those receiving immunosuppressive treatment
Radiographic Progression of Infiltrated Caries Lesions In-vivo

This study is investigating the efficacy of caries lesion infiltration therapy as compared to the current preventative approach for early caries lesions.

A 3-year longitudinal, prospective, randomized control clinical trial (RCT) is designed incorporating a split-mouth intra-oral design. Young volunteers (14-35 years old) with at least two early lesions in posterior teeth will be enrolled into this clinical trial to evaluate the clinical effectiveness of arresting lesion progression by infiltrating the lesions. The infiltration protocol included application of on-market materials and applicators, and was performed in one session.

Eligibility Criteria:
Inclusion Criteria:

* 14-35 year old subjects
* decayed-missing-filled permanent teeth (DMFT) ≥ 3
* having at least two early caries lesions in approximal posterior tooth surfaces
* lesion visible on radiograph

Exclusion Criteria:

* Current participation in another clinical study
* Medically compromised subjects
* Hyposalivation
* Pregnancy
* Allergic to methylmethacrylates
* Allergic to latex
* Symptomatic teeth
Prevalence of Hyperuricemia in Pakistan

The prevalence of hyperuricemia has rarely been investigated in developing countries Hyperuricemia, or raised serum uric acid (SUA), is the condition closely associated with gout due to the deposition of monosodium urate crystals in peripheral joints and soft tissues. Hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors. This risk appears more pronounced in younger individuals and women. Cross-sectional studies show an association of hyperuricemia with the presence of CKD. Insulin resistance plays a potentially key role in the causal relationship between metabolic syndrome, type 2 Diabetes and hyperuricemia. Furthermore, it is likely that hyperuricemia and insulin resistance share a bidirectional causal effect. The rationale of this study is to determine prevalence of hyperuricemia in Pakistan.

Informed consent will be obtained from all patients and their attendant coming to clinics. Those who will agree to be part of this study were asked a questionnaire about co-morbidity and symptoms.

Uric acid levels will be assessed by using UASure Blood Uric Acid Monitoring System. Male with uric acid levels greater than 7 mg/dl and female greater than 6 mg/dl were classified as hyperuricemia.

Eligibility Criteria:
Inclusion Criteria:

* Informed Consent given

Exclusion Criteria:

* No Informed consent provided
De-escalation - Antifungal Treatment Immunocompromised Patients

A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistance, and high cost. Moreover, empirical antifungal treatment is still a matter for debate in these patients. Our study aimed to determine the incidence, associated factors, and safety of de-escalation of antifungals in immunocompromised critically ill patients.

This prospective observational study is conducted in 14 ICU, during a 6 months period. All immunocompromised patients hospitalized for \>5d and treated with antifungals for suspected or proven invasive candida infection will be included De-escalation is defined as a reduction in antifungal spectrum or stopping initial drugs within the 5 days following their initiation. The three antifungals considered in this study are from the narrowest to the widest spectrum: fluconazole, caspofungin and liposomal amphotericin B.

This is a retrospective and prospective observational multicenter study, aiming to determine the incidence, and safety of antifungal de-escalation in immunocompromised patients, and also factors associated with de-escalation.

Eligibility Criteria:
Inclusion Criteria:

* Adults immunocompromised patients hospitalized in intensive care units
* Predictable invasive mechanical ventilation duration \> 96h
* Signed consent (by patient or its representative)
* First antifungal treatment initiation in ICU for proven or suspected candida infection

Exclusion Criteria:

* Pregnant or breast-feeding women.
* Fungal infection other than invasive candida
* Prophylactic antifungal treatment.
* Lack of informed consent
* Predictable mechanical ventilation duration less than 48 hours
* Patients discharged from ICU before the 5th day after initiation of TAF
What SSI Duration is Most Effective? An Online Experiment With American Adults

In a previous study (https://osf.io/qdznc), the research team found that an 8-minute version of a single-session intervention for loneliness was more effective than a 23-minute version of it. The present work aims to further explore the relationship between intervention duration and effectiveness.

In this online trial, participants will be randomized to a 15-minute single-session depression intervention called the Action Brings Change (ABC) Program, a 10-minute version of it, a 6-minute version of it, or a 2-minute version of it. The main analysis will evaluate how change in depressive symptoms over eight weeks differs across conditions.


Eligibility Criteria:
Inclusion Criteria: Participants must be:

* Located in the United States
* At least 18 years old
* Patient Health Questionnaire-8 (PHQ-8) score of at least 10 (moderate or more severe) at screener.
* Able to read and speak fluent English
* Able to access to the internet via a computer, tablet or smartphone for the next eight weeks

Exclusion Criteria:

* Participants who have completed the first session of the study before or completed another study testing a depression intervention from our laboratory via the same participant recruitment platform in the past two months.
Exercise Training in Patients With Rheumatoid Arthritis and Cryotherapy

The main objective of this project is to study, in patients with rheumatoid arthritis, the effects of an intermittent type exercise associated with cryotherapy on the level of inflammation during its recovery.


Eligibility Criteria:
Inclusion Criteria:

* Men and women \>18 years old, \< 80 years old
* Signature of informed consent for participation
* Affiliation to a social security scheme or French beneficiary of such a regime.
* confirmed rheumatoid arthritis and monitoring by the rheumatology department of the University Hospital of Besancon.
* If there is a corticosteroid therapy, it must be stable for at least 1 month and less than or equal to 10 mg of prednisone equivalent per day
* Clinical and biological activity will be moderate (ie not in remission and not severe based on Disease Activity Score 28 joints - DAS 28 - to be between 2 and 6
* Patients could be treated with DMARDs (Disease-Modifying Drugs).

Exclusion Criteria:

* Patient under guardianship, curatorship, under judicial protection, major incapable
* Patients whose body mass index (BMI) greater than 30,
* Pathology incompatible with the completion of a cycle ergometer exercise (heart, vascular, respiratory, orthopedic ...)
* Change in DAS28 greater than 1.2 in the previous 3 months Inclusion
* A patient with a DAS28 \> 6
* about the cold: Raynaud's syndrome, cold known allergy, sickle cell anemia, cryoglobulinemia, uncontrolled hypertension
* Patient unable to follow protocol because of cognitive, psychiatric or language difficulties.
* Inability to follow protocol for causes related to health problems (unrelated Rheumatoid Arthritis) or socio-professional.
Evaluation of Wear Experience With a Daily Disposable Contact Lens

To evaluate the wear experience of current two-week contact lens wearers after they have been fit into a daily disposable contact lens. This is a single arm, non-comparative study.

This is a single arm, non-comparative study. All participants were habitual lens wearers of the same brand of lenses, and were re-fit with the study lenses.

Eligibility Criteria:
Inclusion Criteria:

* Must be current Acuvue® Oasys® spherical contact lens wearers.
* Distance visual acuity of 20/25 or better with current contact lenses.
* Good general health (defined by medication use that has not changed within the last month and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the PI).
* Ability to give informed consent.
* Willing to spend time for the study, which includes attending two study visits and wearing contact lenses on days between study visits.
* Either gender.
* Any racial or ethnic origin.

Exclusion Criteria:

* No current ocular inflammation or infection.
* Not currently pregnant or lactating.
Effect of Saline Lubrication on Post-intubation Complications

The purpose of this study is to evaluate the influence of none-lubricated dry tube on the incidence of Postoperative Sore Throat (POST) after general anesthesia with endotracheal intubation.


Eligibility Criteria:
Inclusion Criteria:

* patients aged between 20-80 years who were scheduled for surgery under general anesthesia requiring orotracheal intubation

Exclusion Criteria:

* history of gastroesophageal reflux disease (GERD)
* congenital or acquired abnormalities of the upper airway such as tumor, polyp, trauma, abscess, inflammation, infection, or foreign bodies
* previous airway surgery; increased risk of aspiration
* coagulation disorders
* previous history of difficult intubation or conditions with expected difficult airway including Mallampati classification ≥ 3 or thyromental distance \< 6.5 cm
* Using the other intubation devices beyond the direct laryngoscopy such as lighted stylet or fiberoptic bronchoscopy
* symptoms of sore throat or upper respiratory tract infection
* expected to place nasogastric tube during perioperative period
* requiring nasotracheal intubation